Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 104138-64-9
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of agalsidase beta during breastfeeding. Because it is a large protein molecule with a molecular weight of about 100,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Six infants who were breastfed for periods up to 12 months by mothers taking the closely related drug agalsidase alfa experienced no adverse effects associated with the drug.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Published information on agalsidase beta was not found as of the revision date. However, some information is available on the closely related drug agalsidase alfa. Six patients with Fabray disease were treated with agalsidase alfa 0.2 mg/kg every 2 weeks during pregnancy and postpartum. One infant partially breastfed for 10 months had asthma at age 4 years and an infant who was partially breastfed for 5 months had recurrent urinary tract infections up to 2 years, but was normal at the age of 5 years. Three infants who were exclusively breastfed for 6 months and partially breastfed until 12 months and one partially breastfed for 12 months were normal. None of the adverse effects appear to have been associated with agalsidase alfa.[1]
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
- Fernández P, Fernández SO, González JGM, et al. Enzyme replacement therapy in pregnant women with Fabry disease A case series. JIMD Rep 2019;45:77-81. [PMC free article: PMC6336548] [PubMed: 30406505]
Substance Identification
Substance Name
Agalsidase Beta
CAS Registry Number
104138-64-9
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Agalsidase Alfa.[Drugs and Lactation Database (...]Review Agalsidase Alfa.. Drugs and Lactation Database (LactMed®). 2006
- Review Dornase Alfa.[Drugs and Lactation Database (...]Review Dornase Alfa.. Drugs and Lactation Database (LactMed®). 2006
- Review Avalglucosidase Alfa.[Drugs and Lactation Database (...]Review Avalglucosidase Alfa.. Drugs and Lactation Database (LactMed®). 2006
- Review Cipaglucosidase Alfa.[Drugs and Lactation Database (...]Review Cipaglucosidase Alfa.. Drugs and Lactation Database (LactMed®). 2006
- Review Factor Xa (recombinant), Inactivated.[Drugs and Lactation Database (...]Review Factor Xa (recombinant), Inactivated.. Drugs and Lactation Database (LactMed®). 2006
- Agalsidase Beta - Drugs and Lactation Database (LactMed®)Agalsidase Beta - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...